Abstract
BACKGROUND: To evaluate the short-term efficacy of denervation in treating hypertension with the exclusion of drug-interfering factors. METHODS: An electronic search was conducted across 8 databases, including MEDLINE, PubMed, Cochrane Library, and EMBASE, for articles on denervation in the treatment of medication-naïve hypertension published from inception to May 2024. All data were meta-analyzed using RevMan 5.3 software. RESULTS: Four studies, comprising a total of 752 subjects, were screened according to the inclusion and exclusion criteria. Meta-analysis indicated that, compared to the sham-operated group, the denervation group showed a significant reduction in short-term 24-hour ambulatory systolic blood pressure and office systolic blood pressure (OSBP) as well as office diastolic blood pressure (ODBP). No significant safety events were identified. CONCLUSION: Denervation has the potential to reduce blood pressure in the short-term for patients with medication-naïve hypertension, demonstrating an acceptable safety profile. This offers hope for patients who are intolerant to drug therapy or unwilling to take lifelong medication. However, its long-term effects require further study. Future research should focus on expanding the sample size and prolonging the follow-up period to further solidify its role in the treatment of hypertension.